sc13g0214plio_karyopharm.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
(Amendment No. ________)*
 
Karyopharm Therapeutics Inc. 

(Name of Issuer)
 
Common Stock 

(Title of Class of Securities)
 
48576U106

(CUSIP Number)
 
Simon Prisk, Esq.
150 East 58th Street, 22nd Floor
New York, NY 10155
(212) 355-3333 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
 
2/14/14 

(Date of Event which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨  Rule 13d-1(b)
¨  Rule 13d-1(c)
x  Rule 13d-1(d)
 
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 


 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 2 of 10 pages

1.
 
NAMES OF REPORTING PERSONS
Plio Ltd.
 
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) N/A
2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
 
(a)    ¨
(b)    ¨
3.
 
SEC USE ONLY
 
 
4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
CYPRUS
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
 
SOLE VOTING POWER
 
0
6.
 
SHARED VOTING POWER
 
3,193,473
7.
 
SOLE DISPOSITIVE POWER
 
0
8.
 
SHARED DISPOSITIVE POWER
 
3,193,473
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,193,473
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ¨
 
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
10.7%
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
CO
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 3 of 10 pages

1.
 
NAMES OF REPORTING PERSONS
Marcin Czernik
 
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
 
(a)    ¨
(b)    ¨
3.
 
SEC USE ONLY
 
 
4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
POLAND
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON WITH
5.
 
SOLE VOTING POWER
 
0
6.
 
SHARED VOTING POWER
 
3,193,473
7.
 
SOLE DISPOSITIVE POWER
 
0
8.
 
SHARED DISPOSITIVE POWER
 
3,193,473
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,193,473
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    x
 
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
10.7%
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
IN, HC
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 4 of 10 pages
 
1.
 
NAMES OF REPORTING PERSONS
Andreas Hadjimichael
 
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
 
(a)    ¨
(b)    ¨
3.
 
SEC USE ONLY
 
 
4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
CYPRUS
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
 
SOLE VOTING POWER
 
0
6.
 
SHARED VOTING POWER
 
3,193,473
7.
 
SOLE DISPOSITIVE POWER
 
0
8.
 
SHARED DISPOSITIVE POWER
 
3,193,473
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,193,473
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    x
 
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
10.7%
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
IN, HC
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 5 of 10 pages

1.
 
NAMES OF REPORTING PERSONS
Amalia Hadjimichael
 
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
 
(a)    ¨
(b)    ¨
3.
 
SEC USE ONLY
 
 
4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
CYPRUS
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
 
SOLE VOTING POWER
 
0
6.
 
SHARED VOTING POWER
 
3,193,473
7.
 
SOLE DISPOSITIVE POWER
 
0
8.
 
SHARED DISPOSITIVE POWER
 
3,193,473
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,193,473
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    x
 
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
10.7%
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
IN, HC
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 6 of 10 pages

1.
 
NAMES OF REPORTING PERSONS
Gregory Jankilevitsch
 
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
 
(a)    ¨
(b)    ¨
3.
 
SEC USE ONLY
 
 
4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
CYPRUS
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
 
SOLE VOTING POWER
 
0
6.
 
SHARED VOTING POWER
 
3,193,473
7.
 
SOLE DISPOSITIVE POWER
 
0
8.
 
SHARED DISPOSITIVE POWER
 
3,193,473
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,193,473
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)    ¨
 
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
10.7%
12.
 
TYPE OF REPORTING PERSON (see instructions)
 
IN, HC
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 7 of 10 pages
 
Item 1.
 
 
(a)
Karyopharm Therapeutics Inc.
     
 
(b)
Address of Issuer’s Principal Executive Offices
2 Mercer Road
Natick, MA 01760
 
Item 2.
 
 
(a)
Name of Person Filing
     
   
This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):
   
 
(i)   Plio Ltd. (“Plio”)
 
(ii)  Marcin Czernik
 
(iii) Andreas Hadjimichael
 
(iv) Amalia Hadjimichael
 
(v)  Gregory Jankilevitsch
     
 
(b)
Address of the Principal Office or, if none, residence
 
(i)   The principal office of each of the Reporting Persons (other than Mr. Jankilevitsch) is Simou Menardou 8, Ria Court 8, Office 101, 6015 Larnaca, Cyprus.
 
(ii)  The residence address of Mr. Jankilevitsch is Route de Genève 71, CH-1180 Rolle, Switzerland.
     
 
(c)
Citizenship
 
(i)   Plio is a Cyprus corporation.
 
(ii)  Mr. Hadjimichael and Ms. Hadjimichael are citizens of the Republic of Cyprus.
 
(iii) Messrs. Czernik and  Jankilevitsch are citizens of the Republic of Poland.
     
 
(d)
Title of Class of Securities
 
Common Stock
     
 
(e)
CUSIP Number
 
48576U106
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 8 of 10 pages
 
Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 
Not applicable.
 
Item 4.  Ownership.
 
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
 
(a)
Amount beneficially owned:  3,193,473 shares. These shares of Common Stock are owned directly by Plio. Plio's directors, Marcin Czernik, Andreas Hadjimichael and Amalia Hadjimichael, and its sole stockholder, Gregory Jankilevitsch, may be deemed to share voting and investment power and beneficial ownership of such shares of Common Stock. Each of such directors and stockholder disclaims such voting and investment power and beneficial ownership.  The number of shares listed on the cover pages of this Schedule 13G pertaining to Plio’s directors includes the shares of Common Stock owned directly by Plio, but does not include 10,258,079 shares of Common Stock (representing 34.5% of the outstanding Common Stock) owned directly by Chione Ltd., which has the same directors and as to which each of such directors may be deemed to share voting and investment power and beneficial ownership.  Each of such directors disclaims such voting and investment power and beneficial ownership.
     
(b)
Percent of class:  10.7%.  See item 4(a) above.
     
(c)
Number of shares as to which the person has:  
 
Plio
     
 
(i)
Sole power to vote or to direct the vote  0.
 
     
 
(ii)
Shared power to vote or to direct the vote  3,193,473.
 
     
 
(iii)
Sole power to dispose or to direct the disposition of  0
 
     
 
(iv)
Shared power to dispose or to direct the disposition of  3,193,473
     
  Mr. Czernik
 
 
(i)
Sole power to vote or to direct the vote  0.
     
 
(ii)
Shared power to vote or to direct the vote  3,193,473.
     
 
(iii)
Sole power to dispose or to direct the disposition of  0
     
 
(iv)
Shared power to dispose or to direct the disposition of  3,193,473
 
 
Mr. Hadjimichael
 
 
(i)
Sole power to vote or to direct the vote  0.
     
 
(ii)
Shared power to vote or to direct the vote  3,193,473.
     
 
(iii)
Sole power to dispose or to direct the disposition of  0
     
 
(iv)
Shared power to dispose or to direct the disposition of  3,193,473
 
 
 

 
 
CUSIP No. 48576U106
 
13G
 
Page 9 of 10 pages
 
 
Ms. Hadjmichael
     
 
(i)
Sole power to vote or to direct the vote  0.
     
 
(ii)
Shared power to vote or to direct the vote  3,193,473.
     
 
(iii)
Sole power to dispose or to direct the disposition of  0
     
 
(iv)
Shared power to dispose or to direct the disposition of  3,193,473
 
 
Mr. Jankilevitsch
     
 
(i)
Sole power to vote or to direct the vote  0.
     
 
(ii)
Shared power to vote or to direct the vote  3,193,473.
     
 
(iii)
Sole power to dispose or to direct the disposition of  0
     
  (iv)
Shared power to dispose or to direct the disposition of  3,193,473
 
See item 4(a) above.
 
Item 5.  Ownership of Five Percent or Less of a Class.
 
Not applicable.
 
Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
 
 Not applicable.
 
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
 
 Not applicable.
 
Item 8.  Identification and Classification of Members of the Group.
 
       Not applicable.
 
Item 9.  Notice of Dissolution of Group.
 
       Not applicable.
 
Item 10.  Certification.
 
Not applicable.
 
 
 

 
 
CUSIP No. 048576U106
 
13G
 
Page 10 of 10 pages
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 
February 18, 2014
 
Date
   
 
Plio Limited, by /s/ Simon Prisk, as attorney-in-fact
 
Marcin Czernik, by /s/ Simon Prisk, as attorney-in-fact
 
Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in-fact
 
Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in-fact
 
Gregory Jankilevitsch, by /s/ Simon Prisk, as attorney-in-fact
 
Exhibit Index
Exhibit 24.1 - Power of Attorney, dated February 12, 2014, made by Marcin Czernik and Plio Limited in favor of Simon Prisk
Exhibit 24.2 - Power of Attorney, dated February 12, 2014, made by Andreas Hadjimichael and Plio Limited in favor of Simon Prisk
Exhibit 24.3 - Power of Attorney, dated February 12, 2014, made by Amalia Hadjimichael and Plio Limited in favor of Simon Prisk
Exhibit 24.4 - Power of Attorney, dated February 12, 2014, made by Gregory Jankilevitsch  in favor of Simon Prisk
Exhibit 99.1 - Joint Filing Agreement, dated February 18, 2014, among the Reporting Persons
 
 

sc13g0214plioex24i_karyo.htm
EXHIBIT 24.1
 
LIMITED POWER OF ATTORNEY
 
The undersigned, Marcin Czernik, hereby appoints Simon Prisk as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Plio Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act.  Such appointment as attorney-in-fact shall include, without limitation, the power and authority:
 
 
1.
to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;
 
 
2.
to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;
 
 
3.
to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and
 
 
4.
to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.
 
The undersigned acknowledges that­­­­­­­­­­ said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.
 
Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.
 
 
 

 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 11, 2015 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.
 
The undersigned is signing this Limited Power of Attorney as of February 12, 2014.
 
  /s/ Marcin Czernik
 
Marcin Czernik, individually, including in his capacity as an officer and/or director of the Company
(as applicable), and on behalf of the Company
 
 
2
sc13g0214plioex24ii_karyo.htm
EXHIBIT 24.2
 
LIMITED POWER OF ATTORNEY
 
The undersigned, Andreas Hadjimichael, hereby appoints Simon Prisk as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Plio Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act.  Such appointment as attorney-in-fact shall include, without limitation, the power and authority:
 
 
1.
to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;
 
 
2.
to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;
 
 
3.
to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and
 
 
4.
to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.
 
The undersigned acknowledges that­­­­­­­­­­ said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.
 
Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.
 
 
 

 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 11, 2015 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.
 
The undersigned is signing this Limited Power of Attorney as of February 12, 2014.
 
  /s/ Andreas Hadjimichael
 
Andreas Hadjimichael, individually, including in his capacity as an officer and/or director of the Company
(as applicable), and on behalf of the Company
 
 
2

sc13g0214plioex24iii_karyo.htm
EXHIBIT 24.3
 
LIMITED POWER OF ATTORNEY
 
The undersigned, Amalia Hadjimichael, hereby appoints Simon Prisk as her attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Plio Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act.  Such appointment as attorney-in-fact shall include, without limitation, the power and authority:
 
 
1.
to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;
 
 
2.
to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;
 
 
3.
to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and
 
 
4.
to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.
 
The undersigned acknowledges that­­­­­­­­­­ said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.
 
Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.
 
 
 

 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 11, 2015 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.
 
The undersigned is signing this Limited Power of Attorney as of February 12, 2014.
 
  /s/ Amalia Hadjimichael
 
Amalia Hadjimichael, individually, including in her capacity as an officer and/or director of the Company
(as applicable), and on behalf of the Company
 
 
2

sc13g0214plioex24iv_karyo.htm
EXHIBIT 24.4
 
LIMITED POWER OF ATTORNEY
 
The undersigned, Gregory Jankilevitsch, hereby appoints Simon Prisk as his attorney-in-fact for and on behalf of the undersigned, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary interest in (whether or not such beneficial ownership or pecuniary interest is disclaimed), securities of Karyopharm Therapeutics Inc., including any successor entity (“KTI”), and (B) any other status, including, if applicable, as an officer or director of Plio Limited (the “Company”), or transaction of or involving the undersigned and/or the Company requiring any filing or report pursuant to the Securities Exchange Act of 1934 and the rules and regulations thereunder or applicable thereto (the “Exchange Act”) in respect of such securities, including, without limitation, pursuant to Section 13 or 16 of the Exchange Act.  Such appointment as attorney-in-fact shall include, without limitation, the power and authority:
 
 
1.
to execute and file a Form ID on behalf of the undersigned and otherwise to secure any codes required in order for the undersigned to be able to file with the U.S. Securities and Exchange Commission’s Edgar system;
 
 
2.
to execute and file any Form 3, Form 4, or Form 5, Schedule 13G or 13D, any amendments to any such Form or Schedule, and any filing agreements related to securities of KTI on behalf of the undersigned and/or the Company;
 
 
3.
to seek and obtain information on behalf of, and as the representative of the undersigned and/or the Company, from any and all persons, including, without limitation, representatives of the Company and KTI, in connection with the foregoing; and
 
 
4.
to do and perform any and all acts and things, including, without limitation, to execute, submit and file such agreements, instruments, forms and other documents, to incur such expenses, as may be necessary or desirable, in the sole discretion of such attorney-in-fact, in connection with the foregoing, it being understood that the documents executed by such attorney-in-fact pursuant to this Limited Power of Attorney shall be in such form and shall contain such information as such attorney-in-fact may approve in such attorney-in-fact’s sole discretion.
 
The undersigned acknowledges that­­­­­­­­­­ said attorney-in-fact is not assuming any of my responsibilities to comply with the Exchange Act.
 
Said attorney-in-fact may (i) act in reliance upon the signature below; and (ii) assume that any person, whether as an individual or as a person who has been designated by the Company or KTI or any other person to give any written instructions, notice or receipt, or make any statements in connection with the foregoing matters (or any of them) has been duly authorized to do so.
 
 
 

 

Said attorney-in-fact shall have no duty to make inquiry as to the genuineness, accuracy or validity of any statements or instructions or any signatures or instructions.   

This Limited Power of Attorney will remain in effect until February 11, 2015 or until such earlier time as a written revocation of this Limited Power of Attorney is delivered to said attorney-in-fact at the then current address of the Ruchelman Law Firm.
 
The undersigned is signing this Limited Power of Attorney as of February 12, 2014.
 
 
/s/ Gregory Jankilevitsch
 
Gregory Jankilevitsch
 
 

sc13g0214plioex99i_karyo.htm
EXHIBIT 99.1
 
JOINT FILING AGREEMENT
 
The undersigned hereby agree that the Schedule 13G with respect to the Common Stock of Karyopharm Therapeutics Inc., dated as of February 18, 2014, is, and any amendments thereto, any Schedule 13D with respect to such Common Stock, and any amendments thereto, signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
 
  Dated:  February 18, 2014
 
 
 
Plio Limited, by /s/ Simon Prisk, as attorney-in-fact
 
Marcin Czernik, by /s/ Simon Prisk, as attorney-in-fact
 
Andreas Hadjimichael, by /s/ Simon Prisk, as attorney-in-fact
 
Amalia Hadjimichael, by /s/ Simon Prisk, as attorney-in- fact
 
Gregory Jankilevitsch, by /s/ Simon Prisk, as attorney-in-fact